Co-Diagnostics (MUN:C97) Price Target Decreased by 32.24% to 1.76

The average one-year price target for Co-Diagnostics (MUN:C97) has been reduced by 32.24% to 1.76 €/share, though this still implies a substantial 1,252.44% upside from its current closing price. Institutional ownership data reveals a 12% decrease in the number of funds holding positions and a 17.10% reduction in total shares owned over the last quarter, despite an increase in the average portfolio weight dedicated to C97 by remaining funds. This mixed sentiment is exemplified by Geode Capital Management reducing its stake, while Renaissance Technologies decreased its portfolio allocation to the stock.

Analysis

The average one-year price target for Co-Diagnostics (MUN:C97) has been significantly revised downwards by 32.24% to 1.76 €/share from a prior estimate of 2.59 € dated October 29, 2025. Despite this reduction, the current target still implies a substantial 1,252.44% upside from the latest closing price of 0.13 €/share, indicating a highly volatile or deeply undervalued perception by analysts. The range of analyst targets, from 0.87 € to 2.71 €, further underscores this divergence in outlook.

Institutional sentiment appears to be moderately negative, with a 12.00% decrease in the number of funds holding C97 positions over the last quarter, reducing the total to 44. Concurrently, total shares owned by institutions declined by 17.10% to 5.119 million shares. This net selling pressure suggests a broader institutional divestment trend.

While overall institutional ownership decreased, the average portfolio weight dedicated to C97 by the remaining funds increased by 64.25%, suggesting that those who maintain positions are, on average, allocating a slightly larger proportion of their portfolios to the stock, albeit from a very low base (0.00%). However, specific actions like Geode Capital Management reducing its stake by 6.93% and Renaissance Technologies decreasing its portfolio allocation by 18.90% despite a minor share increase, reinforce the cautious stance among sophisticated investors.

Key Decisions for Investors

• Investors should exercise caution given the significant downward revision in analyst price targets and the net institutional selling pressure.
• Consider the substantial implied upside of 1,252.44% from the current price against the backdrop of declining institutional interest and the wide range of analyst targets, indicating high risk and uncertainty.
• Monitor future institutional filings for continued divestment trends and any fundamental developments that could justify the extreme implied upside, as current sentiment is moderately negative.